"... In PAGE 4: ... Setting the permutation P H11349 0.05 as a cutoff for significance, 46 common LOH regions were identified across the genome ( Table2 ). By visual inspection of the LOH patterns, we determined that LOH affected each of these regions in at least 18% of the tumors.... ..."

"... In PAGE 1: ... Breast cancer is more common among women in upper social classes than among women in lower social classes, among women who have never been married than in women who have been married, among women living in urban areas than in rural areas, among women living in the Northern United States than in the Southern United States, and among whites than blacks, at least among those over 50 years of age. Women in North American (see Table1 ) and Northern European countries have the highest risk for breast cancer, women in Southern European and Latin American countries are at interme- diate risk, and women in African and Asian countries have the lowest risk. However, rapid rates of increase in incidence rates have been noted in recent years in many Asian, Central European, and some South American countries.... ..."

"... In PAGE 6: ...uclear grade (2.5%, 95% CI H11005 2.1% to 3.0%) ( Table5 ) and lowest for women who were aged 70 years at diagnosis and whose DCIS lesions had a low nuclear grade (0.8%, 95% CI H11005 0.... In PAGE 6: ...1% to 1.2%) ( Table5 ). The 10-year absolute risk of death from other causes was greater for women of all ages who had DCIS that was initially detected by mammography than the 10-year absolute risk of death from invasive breast cancer.... ..."

"... In PAGE 3: ...I H11005 1.0 to 2.1; P H11005 .05) ( Table1 ). Body mass index, use of hormone replacement therapy before or after the initial DCIS diagnosis, oral contraceptive use, family history of breast cancer, menopausal status, race/ethnicity, and DCIS detection method were not associated with recurrence.... ..."

"... In PAGE 25: ... The stage distribution of the invasive cancers at diagnosis was similar to that reported annually in the SEER data base. Results are shown in Table1 . For each endpoint the following results are presented: the number of events and rate per 1,000 women per year for the placebo and tamoxifen groups; and the relative risk (RR) and its associated 95% confidence interval (CI) between tamoxifen and placebo.... In PAGE 26: ... The complete text of the Medication Guide is reprinted at the end of this document. Reduction in Invasive Breast Cancer and DCIS in Women with DCIS Women with DCIS treated with lumpectomy and radiation therapy who are considering tamoxifen to reduce the incidence of a second breast cancer event should assess the risks and benefits of therapy, since treatment with tamoxifen decreased the incidence of invasive breast cancer, but has not been shown to affect survival (See Table1 in CLINICAL PHARMACOLOGY). Reduction in Breast Cancer Incidence in High Risk Women Women who are at high risk for breast cancer can consider taking tamoxifen therapy to reduce the incidence of breast cancer.... ..."

"... In PAGE 2: ... In total, 40 mg total cell lysate from three invasive ductal carcinoma samples, one secondary metastatic liver tumor and nine normal samples, three matched to tumors, were analysed. Each of the four tumor samples exhibited a dramatically higher expres- sion level of p62 relative to normal breast tissue, up to a 122-fold increase ( Table1 ). Samples were normalized to total protein content, as determined by the method of Bradford.... ..."

"... In PAGE 4: ...2. Species that are invasive elsewhere and are likewise invasive or have the potential to become so in American Samoa Some known invasive plants that are causing trouble in similar ecosystems have been introduced into American Samoa (see Appendix 2, Table2 ). Some of them are already causing problems while others are not.... ..."

"... In PAGE 51: ... Each earth model is approximately 1000 feet long and consists of 80 beds. There is a total of 19 models for training, testing and validation as shown in Table5 . During training one calculates the error on a set of examples that is not used during training, the so-called validation set.... In PAGE 74: ...2 % 77 % correct 47485 Shallow-log (2): After this training we add models without invasion and some models with invasion and restart the training. For this purpose we use the whole training set (see Table5 ) (the target logs are now sampled every 1.0 feet) and 40 models without invasion (target logs wer sampled every 0.... ..."

"... In PAGE 10: ...rade 3 and all samples). Highlighted in bold are SAM genes................................. 29 Table3 Top thirty genes using GSEA based on the correlation between their expression and the class distinction in multiple tumor types.... In PAGE 47: ...Mootha el al., 2003; Subramanian et al., 2005) to evaluate genes found to be primarily upregulated (Table 2) on data other than breast tumor, derived from multiple tissue-type tumors (Table 1). The ranking results indicated in Table3 indicate that protein products for genes such as EGFR, IL12B, INHBC, IL12A, IL9, TNF, TNFSF9, and IL4 are potential biomarker candidates for relapse in most solid tissue types. The list also contains in its top twenty other malignancy associated biomarkers such as TNSF18, IL21, JUN, and TGFB1.... In PAGE 47: ...3.7 Relevance of Breast Cancer Cell Lines to Research on Molecular Mechanisms of Relapse in Cancer Our computations shown in Table3 indicated that much of the same genes that are upregulated in breast cancer relapse were also upregulated in highly invasive breast cancer cell lines (BT474, MDAMB231) when compared to poorly invasive MCF7 cell line (Ertel et al., 2006).... In PAGE 54: ... The gene list in Table 2 may be potentially useful in selecting biomarkers for relapse in cancers with solid tumors. Further analysis of the gene set presented in Table 2 with the gene set enrichment tool yielded of ranked gene list ( Table3 ) that appeared to correlate with relapse in a wide variety of cancers listed in Table 1. These results suggest potential genes involved in cell communication and signaling pathways as determinants or biomarkers of relapse in cancer.... ..."